health benefits of glp 1 drugs The GLP-1 revolution: What UAB researchers are discovering about how these work GLP-1 Medications: Everything You Need

Van Woert MH, Mueller PS, Ambani LM, Rathey U

Triggers for initiating a discussion on switching may include HbA 1c targets not being met, the need for additional weight loss, patients moving to an increased cardiovascular risk status and poor adherence

Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial

Still, with the recent introduction of oral semaglutide (Rybelsus), accessibility has improved

[DOI] [PMC free article] [PubMed] [Google Scholar] 6.Filippatos TD, Elisaf MS

Adjudicated four-component major adverse cardiovascular event (MACE-4 events